首页> 外文期刊>Current Pharmaceutical Biotechnology >Pharmacophore,QSAR,and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
【24h】

Pharmacophore,QSAR,and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening

机译:人细胞色素P450 2D6(CYP2D6)底物的药理学,QSAR和结合模式的分子对接和虚拟突变研究及其在中药筛选中的应用

获取原文

摘要

The highly polymorphic human cytochrome P450 2D6 (CYP2D6) metabolizes about 25% of currently used drugs. In this study,we have explored the interaction of a large number of substrates (n = 120) with wild-type and mutated CYP2D6 by molecular docking using the CDOCKER module. Before we conducted the molecular docking and virtual mutations,the pharmacophore and QSAR models of CYP2D6 substrates were developed and validated. Finally,we explored the interaction of a traditional Chinese herbal formula,Fangjifuling decoction,with CYP2D6 by virtual screening. The optimized pharmacophore model derived from 20 substrates of CYP2D6 contained two hydrophobic features and one hydrogen bond acceptor feature,giving a relevance ratio of 76% when a validation set of substrates were tested. However,our QSAR models gave poor prediction of the binding affinity of substrates. Our docking study demonstrated that 117 out of 120 substrates could be docked into the active site of CYP2D6. Forty one out of 117 substrates (35.04%) formed hydrogen bonds with various active site residues of CYP2D6 and 53 (45.30%) substrates formed a strong n-n interaction with Phel20 (53/54),with only carvedilol showing n-n interaction with Phe483. The active site residues involving hydrogen bond formation with substrates included Leu213,Lys214,Glu216,Ser217,Gln244,Asp301,Ser304,Ala305,Phe483,and Phe484. Furthermore,the CDOCKER algorithm was further applied to study the impact of mutations of 28 active site residues (mostly non-conserved) of CYP2D6 on substrate binding modes using five probe substrates including bufuralol,debrisoquine,dextromethorphan,sparteine,and tramadol. All mutations of the residues examined altered the hydrogen bond formation and/or aromatic interactions,depending on the probe used in molecular docking. Apparent changes of the binding modes have been observed with the Glu216Asp and Asp301Glu mutants. Overall,60 compounds out of 130 from Fangjifuling decoction matched our pharmacophore model for CYP2D6 substrates. Fifty four out of these 60 compounds could be docked into the active site of CYP2D6 and 24 of 54 compounds formed hydrogen bonds with Glu216,Asp301,Ser304,and Ala3O5 in CYP2D6. These results have provided further insights into the factors that determining the binding modes of substrates to CYP2D6. Screening of high-affinity ligands for CYP2D6 from herbal formula using computational models is a useful approach to identify potential herb-drug interactions.
机译:高度多态的人类细胞色素P450 2D6(CYP2D6)代谢约25%的当前使用药物。在这项研究中,我们通过使用CDOCKER模块的分子对接研究了许多底物(n = 120)与野生型和突变CYP2D6的相互作用。在进行分子对接和虚拟突变之前,建立并验证了CYP2D6底物的药效基团和QSAR模型。最后,通过虚拟筛选探索了中草药方剂复灵汤与CYP2D6的相互作用。从CYP2D6的20个底物衍生的优化药效基团模型包含两个疏水性特征和一个氢键受体特征,当测试一组验证性底物时,相关性比率为76%。但是,我们的QSAR模型不能很好地预测底物的结合亲和力。我们的对接研究表明120种底物中的117种可以对接CYP2D6的活性位点。 117种底物中的41种(35.04%)与CYP2D6的各种活性位点残基形成氢键,而53种底物(45.30%)与Phel20(53/54)形成强n-n相互作用,只有卡维地洛与Phe483表现出n-n相互作用。涉及与底物形成氢键的活性位点残基包括Leu213,Lys214,Glu216,Ser217,Gln244,Asp301,Ser304,Ala305,Phe483和Phe484。此外,还使用CDOCKER算法研究了CYP2D6的28个活性位点残基的突变(大部分是非保守的)对bufuralol,debrisoquine,dextromethorphan,sparteine和tramadol的5种探针底物的影响。取决于分子对接中使用的探针,所检查残基的所有突变都会改变氢键的形成和/或芳族相互作用。用Glu216Asp和Asp301Glu突变体观察到结合模式的明显变化。总体而言,方吉弗灵汤中130种化合物中有60种与我们的CYP2D6底物药效团模型匹配。这60种化合物中有54种可以对接到CYP2D6的活性位点中,而54种化合物中的24种与CYP2D6中的Glu216,Asp301,Ser304和Ala3O5形成氢键。这些结果为确定底物与CYP2D6结合模式的因素提供了进一步的见解。使用计算模型从草药配方中筛选CYP2D6的高亲和力配体是一种有用的方法,可用于识别潜在的草药-药物相互作用。

著录项

  • 来源
    《Current Pharmaceutical Biotechnology》 |2012年第9期|p.1640-1704|共65页
  • 作者单位

    The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,P.R. China,School of Health Sciences &Health Innovations Research Institute,RMIT University,Bundoora,Victoria 3083,Australia;

    The First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,P.R. China;

    School of Health Sciences &Health Innovations Research Institute,RMIT University,Bundoora,Victoria 3083,Australia;

    School of Health Sciences &Health Innovations Research Institute,RMIT University,Bundoora,Victoria 3083,Australia;

    School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,P.R. China;

    Department of Pharmaceutical Sciences,College of Pharmacy,University of South Florida,Tampa,FL 33612,USA;

    Department of Pharmaceutical Sciences,College of Pharmacy,University of South Florida,Tampa,FL 33612,USA;

    School of Health Sciences &Health Innovations Research Institute,RMIT University,Bundoora,Victoria 3083,Australia,Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 30, Tampa, FL33612, USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    CYP2d6; substrate; inhibitor; molecular docking; pharmacophore; QSAR; chinese herbal medicine; fangjifuling; decoction;

    机译:CYP2d6;基质;抑制剂分子对接药效团中草药汤;

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号